Myasthenia Gravis and Neuromuscular Disorders

Myasthenia gravis is the most recognizable condition within a broader category of neuromuscular disorders — diseases that disrupt the transmission of signals between motor neurons and the muscles they control. This page covers the definition and classification of neuromuscular disorders, the biological mechanisms that drive them, the clinical scenarios in which they present, and the key diagnostic and management decision points that distinguish one condition from another. Understanding this category of disease matters because misclassification leads to delayed treatment and preventable disability, including potentially fatal respiratory failure.

Definition and scope

Neuromuscular disorders encompass diseases affecting the motor unit — a structure that includes the lower motor neuron, its axon, the neuromuscular junction (NMJ), and the muscle fiber itself. The National Institute of Neurological Disorders and Stroke (NINDS) classifies myasthenia gravis as an autoimmune NMJ disorder, distinguishing it from diseases that primarily affect nerve axons (peripheral neuropathies), the anterior horn cells (motor neuron diseases like ALS), or the muscle fibers directly (myopathies and muscular dystrophies).

Myasthenia gravis (MG) affects an estimated 20 per 100,000 people in the United States (NINDS), making it the most common primary NMJ disorder. The defining feature is fatigable muscle weakness — weakness that worsens with sustained activity and improves with rest. This fatigability differentiates MG from most myopathies, where weakness is more fixed, and from motor neuron diseases, where weakness is progressive and non-fatigable.

The scope of neuromuscular disorders spans at least four anatomical loci:

Anterior horn cell diseases — Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), poliomyelitis
Peripheral nerve diseases — Guillain-Barré syndrome (GBS), Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathy (CIDP)
Neuromuscular junction disorders — Myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), botulism
Primary muscle diseases (myopathies) — Duchenne muscular dystrophy, inflammatory myopathies (dermatomyositis, polymyositis), metabolic myopathies

For a broader orientation to how these disorders fit within the nervous system's overall structure, the home page of this resource situates neuromuscular conditions within the full map of neurological disease categories.

How it works

In myasthenia gravis, autoantibodies — most commonly directed against the acetylcholine receptor (AChR) — bind to and functionally reduce the number of available receptors at the NMJ. Acetylcholine released from the motor nerve terminal cannot bind adequately, reducing end-plate potentials below the threshold required to trigger muscle contraction reliably. Approximately 85% of generalized MG cases are AChR antibody-positive (Myasthenia Gravis Foundation of America, MGFA). In the remaining cases, antibodies against muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4) are identified in a subset of patients.

Lambert-Eaton myasthenic syndrome presents a contrasting mechanism. In LEMS, antibodies target voltage-gated calcium channels (VGCCs) on the presynaptic nerve terminal, reducing acetylcholine release rather than receptor availability. This distinction produces a characteristic clinical inversion: LEMS patients often show transient strength improvement with brief, repeated muscle contractions — the opposite of MG's fatigable pattern.

At the regulatory context for neurological conditions, the FDA's approval framework for MG therapies reflects the immunological specificity of these mechanisms. Eculizumab (Soliris), approved by the U.S. Food and Drug Administration (FDA) in 2017 for generalized AChR antibody-positive MG, targets complement component C5, blocking the downstream immune cascade that destroys the NMJ. The FDA's 2021 approval of efgartigimod (Vyvgart) introduced a different mechanistic class — an FcRn antagonist that reduces circulating IgG antibody levels, including pathogenic AChR antibodies.

Electrodiagnostic testing, particularly EMG and nerve conduction studies, is central to localizing the defect within the motor unit. Repetitive nerve stimulation (RNS) at 3 Hz reveals a decremental response in MG (typically a >10% decrement) and an incremental response in LEMS.

Common scenarios

MG follows two primary epidemiological patterns. In women under 40, onset tends to be associated with AChR antibody positivity and, in about 15% of generalized MG cases, a thymoma (NINDS). In men over 60, the seronegative or MuSK-positive subtype is comparatively more frequent, and thymoma association is lower.

The clinical presentation commonly follows this sequence:

Ocular MG — Ptosis (drooping eyelid) and diplopia (double vision) appear first in approximately 50% of MG patients; in 15–20% of cases, disease remains confined to the ocular muscles permanently (MGFA).
Generalized MG — Weakness spreads to bulbar muscles (causing dysarthria and dysphagia), proximal limb muscles, and respiratory muscles.
Myasthenic crisis — Respiratory muscle weakness deteriorates to the point requiring mechanical ventilation; this occurs in approximately 15–20% of MG patients at least once during the disease course (NINDS).

Guillain-Barré syndrome presents an acutely different scenario: ascending flaccid paralysis developing over days to 4 weeks, with absent reflexes and elevated cerebrospinal fluid protein on lumbar puncture. GBS reaches peak weakness by 4 weeks in 90% of patients (NINDS), a time course sharply distinct from MG's fluctuating, activity-dependent pattern.

Decision boundaries

Distinguishing between neuromuscular disorder subtypes requires structured evaluation across four dimensions:

Localization — Does weakness follow a pattern consistent with NMJ (fatigable, proximal-greater-than-distal), nerve (length-dependent, sensory involvement), muscle (proximal symmetric, no sensory loss), or anterior horn cell (fasciculations, mixed upper and lower motor neuron signs)?
Antibody serology — AChR, MuSK, LRP4, anti-VGCC, and anti-ganglioside panels (the last relevant in GBS variants) separate immunological subtypes with treatment implications.
Electrodiagnostic pattern — Decremental RNS (MG) vs. incremental RNS (LEMS) vs. demyelinating conduction slowing (CIDP) vs. axonal loss pattern (GBS axonal variants).
Imaging and biopsy — Chest CT is required in confirmed MG to exclude thymoma. Muscle biopsy differentiates inflammatory from dystrophic and metabolic myopathies when serology is nondiagnostic.

Cholinesterase inhibitors such as pyridostigmine remain the first-line symptomatic treatment for MG across subtypes, but MuSK-positive MG responds poorly to pyridostigmine and requires earlier immunosuppression. This distinction — established in clinical guidelines from the American Academy of Neurology (AAN) — represents a critical decision boundary where antibody subtype directly governs therapeutic sequencing.

Plasma exchange and IVIG are used for acute exacerbations and preoperative stabilization; the mechanisms and indications for both are covered in detail at plasma exchange and IVIG.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)